BioCentury
ARTICLE | Product R&D

Automation navigation

Bringing automation to CAR T cell manufacturing

April 19, 2018 11:58 PM UTC

Last year’s approvals of the first two CAR T therapies have prompted the field to get serious about industrializing manufacturing of the cells to improve reproducibility and lower costs. While stakeholders agree that automation will be essential for both autologous and allogeneic products, there’s debate about how far to take it, and where in the process it’s most valuable.

Like most new technologies, CAR T cell production has started out as a labor-intensive, manual process. ...